Taro shareholders approve merger with Sun Pharma
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Additional data from APPRAISE ATP trial reinforce modular therapy approach
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Subscribe To Our Newsletter & Stay Updated